Source: Renuvion (PRNewswire / Clearwater, Fla.) — Apyx Medical Corporation (NASDAQ: APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the release of a new surgeon testimonial video featuring…
February 27, 2023 – UPDATE: On February 23, 2023, the FDA cleared the Renuvion APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue.The FDA recommendations provided below have not…
July 21, 2022 – UPDATE: The FDA provided an update to this safety communication. Read “Use of Renuvion/J-Plasma Device for Certain Aesthetic Procedures: FDA Safety Communication” for the latest information. Date Issued: June 2, 2022 The U.S. Food and Drug Administration…
The FDA has provided updates to this safety communication:July 21, 2022 – UPDATE: Use of Renuvion/J-Plasma Device for Certain Aesthetic Procedures: FDA Safety CommunicationJune 2, 2022 – UPDATE: FDA Updates Recommendations for the Use of Renuvion/J-Plasma Device for Certain Aesthetic Procedures: FDA Safety Communication…
Surgical Times provides objective public interest reporting on the practice of plastic surgery and is not affiliated with or funded by any surgeon or practice.